BMS Bets on Flexible Capacity With $2.3B Texas Campus

Bristol Myers Squibb is investing $2.3 billion in a flexible, modular manufacturing campus in Houston, Texas, designed for multi-modality drug production. This move aligns with a broader reshoring trend in US biopharma manufacturing driven by tariff volatility and state incentives, aiming to improve supply chain resilience and reduce time-to-market.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.